Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer

Seminars in Oncology

Volumn 39, Issue 5, 2012, Pages 588-597

  Raghavan, Derek ^a   Burgess, Earle ^a   Gaston, Kris E ^a   Haake, Michael R ^a   Riggs, Steven B ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; MESSENGER RNA; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P53; TAXANE DERIVATIVE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BLADDER; BLADDER CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CYSTECTOMY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE BLADDER CANCER; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; META ANALYSIS; METASTASIS; MOLECULAR GENETICS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; URINARY BLADDER NEOPLASMS;

EID: 84867006848     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.08.003     Document Type: Article

References (70)

1. R. Siegel, D. Naishadham, A. Jemal Cancer statistics, 2012 CA Cancer J Clin 58 2012 71
2. D. Raghavan, W.U. Shipley, M.B. Garnick, P.J. Russell, J.P. Richie Biology and management of bladder cancer N Engl J Med 322 1990 1129 1138
3. Siefker-Radtke A, Czerniak B, Dinney CP, Millikan RE. Uncommon cancers of the bladder. In: Raghavan D, Blancke C, Johnson DJ, Moots P, et al, editors. Textbook of uncommon cancer. 4th ed. London: Wiley Liss; in press.
4. D. Raghavan, R. Huben Management of bladder cancer Curr Prob Cancer 14 1995 1 64
5. J.P. Stein, G. Lieskovsky, R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666
6. L. Stamatakis, G. Godoy, S. Lerner Innovations in radical cystectomy and lymph node dissection Semin Oncol 39 2012 573 582
7. J.W. Davis, K. Gaston, R. Anderson Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection J Urol 185 2011 79 83
8. T.K. Choueiri, D. Raghavan Chemotherapy for muscle-invasive bladder cancer treated with radiotherapy - persisting uncertainties Nature Clin Pract Oncol 5 2008 444 454
9. H. Sandler, A.J. Mirhadi Current role of radiation therapy for bladder cancer Semin Oncol 39 2012 583 587
10. J. Vieweg, J.E. Gschwend, H.W. Herr, W.R. Fair Pelvic lymph node dissection can be curative in patients with node positive bladder cancer J Urol 161 1999 449
11. D. Raghavan, B. Pearson, G. Coorey Intravenous cisplatinum for invasive bladder cancer: Safety and feasibility of a new approach Med J Aust 140 1984 276 278
12. D. Raghavan, B. Pearson, P. Duval Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer? J Urol 133 1985 399 402
13. H.W. Herr Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer J Urol 123 1980 853
14. M.S. Soloway, M. Ikard, J. Ford Cis-diamminedichloroplatiinum (II) in locally advanced and metastatic urothelial cancer Cancer 47 1981 476
15. D. Raghavan, I. Tannock Clinical trials in genitourinary cancer: what have they achieved? P.H. Smith, Genitourinary cancer 1990 Springer Verlag New York 225 253
16. H.I. Scher, A. Yagoda, H.W. Herr Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion J Urol 139 1988 470
17. P. Schultz, H.W. Herr, Z.F. Zhang Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up J Clin Oncol 12 1994 1394
18. D.M.A. Wallace, D. Raghavan, K.A. Kelly Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder Br J Urol 67 1991 608 615
19. J.A. Martinez-Pineiro, M. Gonzalez Martin, F. Arocena Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study J Urol 153 1995 964
20. C.N. Sternberg, A. Yagoda, H.I. Scher M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse Cancer 64 1989 2448
21. P. Loehrer, L.H. Einhorn, P.J. Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study J Clin Oncol 10 1992 1066
22. S.D. Fossa, S.J. Harland, S.B. Kaye, D. Raghavan Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 1992 161 168
23. International Collaboration of Trialists Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial Lancet 354 1999 533
24. International Collaboration of Trialists (Griffiths G, Sylvester R, Hall RR, Raghavan D, Parmar MK, writing committee) International phase III trial assessing neoadjuvant cisplatin, methotrexate, vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
25. H.B. Grossman, R.B. Natale, C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
26. H.W. Herr, J.R. Faulkner, H.B. Grossman Surgical factors influence bladder cancer outcomes: a cooperative group report J Clin Oncol 22 2004 2781
27. E. Scosyrev, B.W. Ely, E.M. Messing Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-directed Intergroup Study (S8710) BJU Int 108 2011 693 699
28. P.U. Malmstrom, E. Rintala, R. Wahlqvist Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial I The Nordic Cooperative Bladder Cancer Study Group J Urol 155 1996 1903 1906
29. A. Sherif, E. Rintala, O. Mestad Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2 Scand J Urol Nephrol 36 2002 419 425
30. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927 1934
31. W.U. Shipley, D.S. Kaufman, N.M. Heney, A.F. Althausen, A.L. Zietman An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy J Urol 160 1999 445 450
32. W.U. Shipley, A.L. Zietman, D.S. Kaufman, J.J. Coen, H.M. Sandler Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates - the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences Semin Radiat Oncol 15 2005 36 41
33. W.U. Shipley, K.A. Winter, D.S. Kaufman Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 J Clin Oncol 16 1998 3576 3583
34. D.G. Skinner, J.R. Daniels, C.A. Russell The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial J Urol 145 1991 459 464
35. M. Stockle, W. Meyenburg, S. Wellek Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: results of a controlled prospective study J Urol 148 1992 302 307
36. M. Stockle, W. Meyenburg, S. Wellek Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience J Urol 153 1995 47 52
37. F. Freiha, J. Reese, F.M. Torti A randomized trial of radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer J Urol 155 1996 495 500
38. Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01. Proc Am Soc Clin Oncol.
39. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) versus cisplatin/gemcitabine (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup study 30987. J Clin Oncol. 30:1107-113.
40. W.M. Stadler, S.P. Lerner, S. Groshen Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on P53 status J Clin Oncol 29 2011 3044 3049
41. R.S. Svatek, S.F. Shariat, R.E. Lasky The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the bladder Clin Cancer Res 16 2010 4461 4467
42. R. Millikan, C. Dinney, D. Swanson Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant m-vac versus cystectomy with both preoperative and postoperative m-vac J Clin Oncol 19 2001 4005 4013
43. H.W. Herr, S.M. Donat Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy J Urol 165 2001 62
44. J. Leissner, R. Hohenfellner, J.W. Thuroff, H.K. Wolf Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis BJU Int 85 2000 817
45. M.S. Wosnitzer, G.W. Hruby, A.M. Murphy A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aNo-N2Mo bladder cancer Cancer 118 2012 358 364
46. A.P. Mitra, D.E. Hansel, R.J. Cote Prognostic value of cell-cycle regulation biomarkers in bladder cancer Semin Oncol 39 2012 524 533
47. D. Esrig, D. Elmajian, S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259
48. A. Sarkis, D. Bajorin, V. Reuter Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC J Clin Oncol 13 1995 1384 1390
49. M.A. Kuczyk, C. Bokemeyer p53 overexpression as a prognostic factor for advanced stage bladder cancer Eur J Cancer 31A 1995 2243
50. M. Tsuji, K. Kojima, Y. Murakami Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens Br J Urol 79 1997 367 372
51. H.W. Herr, D.F. Bajorin, H.I. Scher Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol 161 1999 20
52. R. Cote, D. Esrig, S. Groshen, P.A. Jonas, D.G. Skinner p53 and the treatment of bladder cancer Nature 385 1997 123 125
53. W. Choi, J.B. Shah, M. Tran p63 expression defines a lethal subset of muscle-invasive bladder cancers PLoS One 7 2012 e30206
54. P. Puig, P. Capodieci, M. Drobnjak p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer Clin Cancer Res 9 2003 5642 5651
55. C.O. Leong, N. Vidnovic, M.P. DeYoung, D. Sgroi, L.W. Ellisen The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J Clin Invest 117 2007 1370 1380
56. A. Font, M. Taron, J.L. Gago BRCA 1 mRNA expression and outcome to neoadjvuatn cisplatin-based chemotherapy in bladder cancer Ann Oncol 22 2011 139 144
57. R. Altaha, X. Liang, J.J. Yu, E. Reed Excision repair cross complementing-group 1: gene expression and platinum resistance Int J Mol Med 14 2004 959 970
58. K.A. Olaussen, A. Dunant, P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
59. A.C. Hoffmann, P. Wild, C. Leicht MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy Neoplasia 12 2010 628 636
60. A. Kawashima, M. Nakayama, Y. Kakuta Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer Clin Cancer Res 17 2011 2561 2569
61. R. Takata, T. Katagiri, M. Kanehira Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling Clin Cancer Res 11 2005 2625 2636
62. S.C. Smith, A.S. Baras, G. Dancik A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment Lancet Oncol 12 2011 137 143
63. H. von der Maase, S.W. Hansen, J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068
64. S. Sadeghi, J.A. Garcia Current status of targeted therapy in metastatic urothelial cancer Semin Oncol 39 2012 608 615
65. R.S. Pruthi, M. Nielsen, S. Heathcote A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results BJU Int 106 2010 349 354
66. N.D. James, S.A. Hussain, E. Hall Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer N Engl J Med 366 2012 1477 1488
67. M.P. Porter, M.C. Kerrigan, B.M. Donato, S.D. Ransey Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer Urol Oncol 29 2011 252 258
68. K.A. David, M.I. Milowsky, J. Ritchey, P.R. Carroll, D.M. Nanus Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the national cancer data base J Urol 178 2007 451
69. B.J.W. Miles, A.S. Fairey, M. Eliasziw referral and treatment rates of neoadjvuant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline Can Urol Assoc J 4 2010 263 267
70. G.V. Raj, S. Karavadia, B. Schlomer Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer Cancer 117 2011 276 282